Par Pharmaceutical Inc, one of the operating companies of Endo International plc (OTC: ENDPQ), announced on Friday that it has started shipping the first generic version of Allergan's Pylera(R) (bismuth subcitrate potassium, metronidazole, tetracycline hydrochloride) 140 mg, 125 mg and 125 mg capsules in the US.
The company has taken this step subsequent to US Food and Drug Administration approval of its Abbreviated New Drug Application.
Bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride capsules, along with omeprazole, are aimed at treating patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past five years) to eradicate H. pylori.
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US
Aurisco announces Yangzhou, China manufacturing site's successful FDA inspection
Teva Pharmaceuticals and Alvotech expand biosimilars partnership in the US
Sandoz to invest USD90m in Biosimilar Technical Development Center in Slovenia
Brenzavvy Now Available for the Treatment of Adults with Type 2 Diabetes
Dr. Reddy's Proposed Rituximab Biosimilar Application Accepted for Review by USFDA, EMA and MHRA
Dr. Reddy's rituximab biosimilar candidate undergoes regulatory review in the US, EU and UK
Grossman Named President and Chief Medical Officer at Coya Therapeutics
Endo International launches first generic version of Merck's Noxafil